| Ytd | 177.41% | |
| 1y | -18.60% |
| Open | 2.11 | Prev Close | 2.09 | Low | 2.07 | High | 2.14 | Mkt Cap | 133.83M |
| Vol | 174.75K | Avg Vol | 369.72K | EPS | -0.54 | P/E | N/A | Forward P/E | -14.31 |
| Beta | -0.02 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-13 | 50-d Avg | 2.17 | 200-d Avg | 1.83 | 1yr Est | 15.00 |
HURA News
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno
TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the
TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "
TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript
Citizens analyst Silvan Turkcan reiterates TuHURA Biosciences (NASDAQ:HURA) with a Market Outperf
TuHURA Biosciences NASDAQ: HURA outlined plans for its late-stage immuno-oncology pipeline at the Ca
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analy
TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "
TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno
The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA)
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which missed the ana
TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "
TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "C
Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 resul
Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development TAMPA,
TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.c
Distinguished physician with a career spanning over 29 years in drug development and medical affairs
TuHURA Biosciences, Inc. (NASDAQ: HURA - Get Free Report) dropped 3.1% on Friday. The stock traded a
TAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "
TAMPA, Fla., Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "
TBS-2025 to be investigated in combination with a menin inhibitor in mutNPM1 r/r AML TAMPA, Fla., Fe
TAMPA, Fla., Feb. 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "
TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "C